

Suvorexant Formulation

Version Revision Date: SDS Number: Date of last issue: 10/16/2020
5.6 04/09/2021 21525-00019 Date of first issue: 10/14/2014

SECTION 1. IDENTIFICATION

Product name : Suvorexant Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 2000 Galloping Hill Road
 Kenilworth - New Jersey - U.S.A. 07033
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com


Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with the Hazardous Products Regulations**

Specific target organ toxicity : Category 2 (Central nervous system)
- repeated exposure (Oral)

GHS label elements

Hazard pictograms : 

Signal Word : Warning

Hazard Statements : H373 May cause damage to organs (Central nervous system)
through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
P260 Do not breathe dust.
Response:
P314 Get medical attention if you feel unwell.
Disposal:
P501 Dispose of contents and container to an approved waste
disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

Suvorexant Formulation

Version 5.6 Revision Date: 04/09/2021 SDS Number: 21525-00019 Date of last issue: 10/16/2020
 Date of first issue: 10/14/2014

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | Common Name/Synonym | CAS-No. | Concentration (% w/w) |
|--------------------|---|--------------|-----------------------|
| Suvorexant | No data available | 1030377-33-3 | $\geq 5 - < 10$ * |
| Magnesium stearate | Octadecanoic acid, magnesium salt (2:1) | 557-04-0 | $\geq 1 - < 5$ * |

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
 When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
 Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.
 Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
 Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
 Get medical attention if symptoms occur.
 Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May cause damage to organs through prolonged or repeated exposure if swallowed.
 Contact with dust can cause mechanical irritation or drying of the skin.
 Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
 Alcohol-resistant foam
 Carbon dioxide (CO₂)
 Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
 Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

Suvorexant Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 10/16/2020 |
| 5.6 | 04/09/2021 | 21525-00019 | Date of first issue: 10/14/2014 |

| | | |
|--|---|---|
| ucts | | Metal oxides |
| Specific extinguishing methods | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area. |
| Special protective equipment for fire-fighters | : | In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment. |

SECTION 6. ACCIDENTAL RELEASE MEASURES

| | | |
|---|---|--|
| Personal precautions, protective equipment and emergency procedures | : | Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions | : | Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for containment and cleaning up | : | Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |

SECTION 7. HANDLING AND STORAGE

| | | |
|-------------------------|---|---|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. |

Suvorexant Formulation

Version 5.6 Revision Date: 04/09/2021 SDS Number: 21525-00019 Date of last issue: 10/16/2020
 Date of first issue: 10/14/2014

Take precautionary measures against static discharges.
 Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
 Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|--------------------|--------------|--|--|-----------|
| Suvorexant | 1030377-33-3 | TWA | 20 µg/m ³ (OEB 3) | Internal |
| | | Wipe limit | 200 µg/100 cm ² | Internal |
| Magnesium stearate | 557-04-0 | TWA | 10 mg/m ³ | CA AB OEL |
| | | TWA | 10 mg/m ³ | CA BC OEL |
| | | TWA (Inhalable particulate matter) | 10 mg/m ³ | ACGIH |
| | | TWA (Respirable particulate matter) | 3 mg/m ³ | ACGIH |

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
 Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Suvorexant Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 10/16/2020 |
| 5.6 | 04/09/2021 | 21525-00019 | Date of first issue: 10/14/2014 |

- Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
-

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : powder
- Color : No data available
- Odor : No data available
- Odor Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : Not applicable
- Evaporation rate : Not applicable
- Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
- Flammability (liquids) : No data available
- Upper explosion limit / Upper flammability limit : No data available
- Lower explosion limit / Lower flammability limit : No data available
- Vapor pressure : Not applicable
- Relative vapor density : Not applicable
- Relative density : No data available

Suvorexant Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 10/16/2020 |
| 5.6 | 04/09/2021 | 21525-00019 | Date of first issue: 10/14/2014 |

| | | |
|--|---|--|
| Density | : | No data available |
| Solubility(ies) | : | |
| Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | Not applicable |
| Autoignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| Viscosity | : | |
| Viscosity, kinematic | : | Not applicable |
| Explosive properties | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Molecular weight | : | No data available |
| Particle size | : | No data available |

SECTION 10. STABILITY AND REACTIVITY

| | | |
|------------------------------------|---|--|
| Reactivity | : | Not classified as a reactivity hazard. |
| Chemical stability | : | Stable under normal conditions. |
| Possibility of hazardous reactions | : | May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents. |
| Conditions to avoid | : | Heat, flames and sparks. Avoid dust formation. |
| Incompatible materials | : | Oxidizing agents |
| Hazardous decomposition products | : | No hazardous decomposition products are known. |

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Suvorexant:**

| | | |
|---------------------|---|---------------------------|
| Acute oral toxicity | : | LD50 (Rat): > 1,200 mg/kg |
| | | LD50 (Dog): > 1,125 mg/kg |

Suvorexant Formulation

Version 5.6 Revision Date: 04/09/2021 SDS Number: 21525-00019 Date of last issue: 10/16/2020
Date of first issue: 10/14/2014

LDLo (Mouse): 2,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:**Suvorexant:**

Species : Rabbit
Result : No skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Suvorexant:**

Species : Bovine cornea
Result : Mild eye irritation
Method : Bovine cornea (BCOP)

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Suvorexant Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 10/16/2020 |
| 5.6 | 04/09/2021 | 21525-00019 | Date of first issue: 10/14/2014 |

Components:

Suvorexant:

Test Type : Local lymph node assay (LLNA)
 Species : Mouse
 Assessment : Does not cause skin sensitization.
 Result : negative

Magnesium stearate:

Test Type : Maximization Test
 Routes of exposure : Skin contact
 Species : Guinea pig
 Method : OECD Test Guideline 406
 Result : negative
 Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

Suvorexant:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Test Type: Alkaline elution assay
 Test system: rat hepatocytes
 Result: negative

Test Type: Chromosomal aberration
 Test system: Chinese hamster ovary cells
 Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
 Species: Mouse
 Result: negative

Test Type: Micronucleus test
 Species: Rat
 Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
 Result: negative
 Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
 Method: OECD Test Guideline 473
 Result: negative
 Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Suvorexant Formulation

Version 5.6 Revision Date: 04/09/2021 SDS Number: 21525-00019 Date of last issue: 10/16/2020
Date of first issue: 10/14/2014

Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Suvorexant:**

Species : Mouse
Application Route : Oral
Exposure time : 6 month(s)
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:**Suvorexant:**

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Oral
General Toxicity Parent: NOAEL: \geq 325 mg/kg body weight
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rabbit, female
Application Route: Oral
Developmental Toxicity: NOAEL: 150 mg/kg body weight
Result: negative

Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 80 mg/kg body weight
Result: negative

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion

Suvorexant Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 10/16/2020 |
| 5.6 | 04/09/2021 | 21525-00019 | Date of first issue: 10/14/2014 |

| | | |
|-------------------|---|-----------------------------|
| Target Organs | : | Blood |
| Species | : | Rat |
| NOAEL | : | 40 mg/kg |
| LOAEL | : | 80 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 18 Months |
| Target Organs | : | Eye, Central nervous system |

Magnesium stearate:

| | | |
|-------------------|---|--------------------------------------|
| Species | : | Rat |
| NOAEL | : | > 100 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 90 Days |
| Remarks | : | Based on data from similar materials |

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Suvorexant:

| | | |
|-----------|---|--|
| Ingestion | : | Symptoms: Drowsiness, Headache, abnormal dreams, Fatigue, Dizziness, dry mouth, Nausea, liver function change, upper respiratory tract infection, urinary tract infection, Cough, Diarrhea, Palpitation, tachycardia |
|-----------|---|--|

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Suvorexant:

| | | |
|---|---|--|
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Mysidopsis bahia (opossum shrimp)): 0.56 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 |
| Toxicity to algae/aquatic plants | : | EC50 (Pseudokirchneriella subcapitata (green algae)): > 5 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 2.5 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| Toxicity to fish (Chronic toxicity) | : | NOEC (Pimephales promelas (fathead minnow)): 0.14 mg/l Exposure time: 32 d Method: OECD Test Guideline 210 |

Suvorexant Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 10/16/2020 |
| 5.6 | 04/09/2021 | 21525-00019 | Date of first issue: 10/14/2014 |

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability

Components:

Suvorexant:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 81 %

Suvorexant Formulation

Version 5.6 Revision Date: 04/09/2021 SDS Number: 21525-00019 Date of last issue: 10/16/2020
Date of first issue: 10/14/2014

Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: < 10 %(5 d)
Method: OECD Test Guideline 111

Magnesium stearate:

Biodegradability : Result: Not biodegradable.
Remarks: Based on data from similar materials

Bioaccumulative potential**Components:****Suvorexant:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 358
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.04

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Suvorexant Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 10/16/2020 |
| 5.6 | 04/09/2021 | 21525-00019 | Date of first issue: 10/14/2014 |

Domestic regulation**TDG**

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION**The ingredients of this product are reported in the following inventories:**

| | | |
|-------|---|----------------|
| AICS | : | not determined |
| DSL | : | not determined |
| IECSC | : | not determined |

SECTION 16. OTHER INFORMATION**Full text of other abbreviations**

| | | |
|-----------------|---|---|
| ACGIH | : | USA. ACGIH Threshold Limit Values (TLV) |
| CA AB OEL | : | Canada. Alberta, Occupational Health and Safety Code (table 2: OEL) |
| CA BC OEL | : | Canada. British Columbia OEL |
| ACGIH / TWA | : | 8-hour, time-weighted average |
| CA AB OEL / TWA | : | 8-hour Occupational exposure limit |
| CA BC OEL / TWA | : | 8-hour time weighted average |

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Na-

Suvorexant Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 10/16/2020 |
| 5.6 | 04/09/2021 | 21525-00019 | Date of first issue: 10/14/2014 |

tions; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/09/2021
Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8